- Home
- BTAI
as 09-05-2025 4:00pm EST
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 52.7M | IPO Year: | 2018 |
| Target Price: | $40.00 | AVG Volume (30 days): | 14.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.17 - $13.36 | Next Earning Date: | 08-12-2025 |
| Revenue: | $868,000 | Revenue Growth: | -63.88% |
| Revenue Growth (this year): | -64.19% | Revenue Growth (next year): | 597.46% |
Latest BioXcel Therapeutics Inc. News
BTAI Breaking Stock News: Dive into BTAI Ticker-Specific Updates for Smart Investing
MT Newswires
2 months ago
BioXcel Therapeutics Gets Patent Allowance for Targeted Use of Igalmi in Bipolar, Schizophrenia Patients
GlobeNewswire
3 months ago
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
GlobeNewswire
3 months ago
BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement
Zacks
4 months ago
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
GlobeNewswire
4 months ago
BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Simply Wall St.
5 months ago
BioXcel Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Zacks
5 months ago
BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates
GlobeNewswire
5 months ago
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024
Compare BTAI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BTAI BioXcel Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.